Get started

Obesity

Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
MCD is topped out the long fast food trend may be SHORTMCD lives on people liking what they eat and eating a lot of it. The Happy Meal is famous. into the business model comes the new wave biologics for obesity and diabetes. the shots that cut down the weight and the food addiction. Insurance companies are jumping on the bandwagon. 1/3 of the people eat half the food. Increasingly, those people are seeking treatment. The fastfood executives know this. Same for the sugar beverages. Anyway, enough said. MC on the monthly chart is stuck at a double top even more obvious on a weekly or daily chart. At present it is stuck in a symmetrical triangle compressing price. The mathematical predictive algorithm forecasts price will move down the remainder of this year. I respect the mathematics and understand the medical trend. LLY makes money supplying insulin and now it makes money actually reversing diabetes and obesity. One way or another it makes money and MCD is supplying the patient flow. In the meanwhile if those patients are detoxified and lower their caloric intake, MCD is the one that suffers a regression of the growth story. I am short MCD and add to my position whenever there is a little upward price movement. Yeah, comarketing donuts with Krispy is an act of desperation.
NYSE:MCDShort
by AwesomeAvani
CMG to split price SHORTCMG has announced a split. Makes sense to make shares more affordable but fractionals are widely available. CMG may be fundamentally challenged by the underpinnings of the fast food markets. that is overeating and rising prices. In the meanwhile the anti-obesity and anti- diabetes trends are pushing hard led by the bological injectable meds from LLY, NVO and others. One third of the people eat one half of the food and now an effective treatment for that addiction is becoming increasingly available. The writing is on the wall and food biz executives can read that writing. Enough said. I am going short on CMG. It's best days of growth may behind it. The company announced plans for 4000 more stores nationwide. Really? Time will tell. I vote with my wallet. My position will not be small. The predictive algo has its forecast. My education included both medicine and engineering. I understand the power of biology and mathematics. I deeply respect both.
NYSE:CMGShort
by AwesomeAvani
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
LLY Earnings Play LONG ( Flat Bottom Triangle Breakout)My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one day until earnings. My thesis is the earnings will stimulate what will be a breakout from a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit challenged with the fall off in Covid vaccine work. If you find this idea interesting and might appreciate my ideas as to a stop loss and targets, leave a comment. Like and subscribe. Trade well !
NYSE:LLYLong
by AwesomeAvani
1
RSLS ReShape Lifesciences Price Target- ReShape leader in weight loss market - FDA approved Lap-Band manufacturing moved to the US - eliminated debt overhang - ReShape Marketplace - digital health solution June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million. ReShape Market Cap only 50.061M Shares Outstanding 17.20M On 7/1/2021, Ben Haynor from Alliance Global Partners brokerage Lowered the Price Target from $18.50 to $13.75 My price target is the 9.6usd resistance. I`m looking forward to read your opinion about RSLS.
NASDAQ:RSLSLong
by TopgOptions
7
RSLS ReShape Lifesciences Global Weight-Loss Leader | $ TargetOn 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50! ReShape Lifesciences is America's premier weight-loss solutions company. The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. Reshapecare™ virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. (accesswire.com) My price target is 12usd short term.
NASDAQ:RSLSLong
by TopgOptions
7